• The development of organic molecules which function as a catalyst has been extensively investigated to achieve selective and efficient transformation of organic molecules. Brønsted acids and bases are commonly employed as the catalyst in synthetic organic chemistry. To aim at their functionalization, axially chiral phosphoric acids and axially chiral guanidine bases have been developed as chiral Brønsted acid and base catalysts, respectively. A variety of optically active compounds has been synthesized through the development of highly stereoselective reactions using these catalysts.

The development of chiral Brønsted acid and base catalysts has been accomplished as recoverable and reusable organocatalysts and highly stereoselective molecular transformations have been established using these catalysts. The present methodology is applicable to process chemistry in preparing medicines and relevant compounds on the basis of the selective and efficient molecular transformations thus developed with reduction of the waste material.

• Complexity of the cardiac contraction sequence is still not fully understood because the dynamic mechanical excitation process, which directly correlates with contraction, cannot be accurately measured by CT, MRI, SPECT, or conventional ultrasound. By developing a noninvasive novel imaging modality with high temporal and spatial resolutions (US patent 5840028), we have detected the minute mechanical response (velocity component) to the propagation of the action potential in the human heart or to detect the propagation of the vibrations along the heart wall caused by the valve closure (Fig. 2).
• By applying the same procedure to the human arteries, the regional change in wall thickness caused during one cardiac cycle can be measured with high spatial resolution (Fig. 1). From the measurement, the regional elasticity of tissue surrounding atherosclerotic plaque can be determined. By comparing the pathological findings with the distribution of elasticity, elasticity of lipid and that of fibrous tissue were determined. Thus, each point inside the plaque is classified into lipid or fibrous tissue using transcutaneous ultrasound (Fig. 3).

This novel method offers potential as a diagnostic technique for detection of plaque vulnerability with high spatial resolution.
We are prepared to provide academic consultations to companies interested in our research.

• Eleven strains of recombinant inbred (RI) mice derived from MRL/lpr and C3H/lpr mice were established. This RI is the only one in the world that randomly develops lesions such as nephritis, arthritis, sialadenitis, vasculitis, and production of autoantibodies in each strain. The genomes of the two strains of mice are randomly held in homozygous condition, and the phenotypes of each strain and the effects of administered drugs could be compared based on their genotype maps. It is possible to identify the regions of gene loci involved in the phenotype and drug sensitivity.

Development of diagnostic and therapeutic agents for autoimmune diseases. It can be applied to the elucidation of the mechanism of onset of immunological adverse events caused by immune checkpoint inhibitors and the development of drugs to prevent the onset of such events, and industry-academia collaboration with pharmaceutical companies, test reagent companies, etc. is possible.

• Metabolic syndrome is an important view point, when we consider the preventive medicine. Hypertension is one of the most important points to prevent the cardiovascular events. However, there is no method to measure the baroreflex sensitivity of the artery in the patients with hypertension. Tohoku University had invented the new method to evaluate the baroreflex sensitivity of the heart and artery (JP Patent No.4789203).

By the use of this machine, the baroreflex sensitivity of an artery in the patients can easily be measured noninvasively. It enables to predict the occurrence of hypertension and evaluate the therapy of hypertension easily, while allowing prevention of the cardiovascular events.

• Dr. Katsunori Nonogaki has developed the novel ultrasound irradiation device, which can improve the autonomic nervous system activity and peripheral circulation. In addition, the ultrasoud device can improve hypertension and hyperglycemia within 20 min in subjects with drug-resistant hypertension and diabetes. Our initial device was approved in Japan (226AIBZX00028000). This device will be avaliable for the treatment of 1) muscle pain, 2) the autonomic neural dysfunction and stress-related disorders, 3) hypertention, and 4) diabetes. Moreover, the device will be usefull for your healthy life and aging care.

Our aims are to export the device internationally. We seek the investment and international business partners.